GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA
Apart from already established clinical factors, the polymorphic loci of the VEGF gene and its VEGFR2 receptor can have a significant effect on the response to anti-VEGF therapy of diabetic macular edema. The aim was to study the association of single nucleotide polymorphic loci of VEGF and VEGFR2 g...
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | Russian |
| Опубликовано: |
Russian Academy of Sciences, Siberian Branch Publishing House
2019-02-01
|
| Серии: | Сибирский научный медицинский журнал |
| Предметы: | |
| Online-ссылка: | https://sibmed.elpub.ru/jour/article/view/60 |
| _version_ | 1826575783499399168 |
|---|---|
| author | A. Z. Fursova N. V. Chubar M. S. Tarasov M. A. Vasilyeva S. A. Erkinova A. S. Shadrina E. A. Sokolova M. L. Filipenko |
| author_facet | A. Z. Fursova N. V. Chubar M. S. Tarasov M. A. Vasilyeva S. A. Erkinova A. S. Shadrina E. A. Sokolova M. L. Filipenko |
| author_sort | A. Z. Fursova |
| collection | DOAJ |
| description | Apart from already established clinical factors, the polymorphic loci of the VEGF gene and its VEGFR2 receptor can have a significant effect on the response to anti-VEGF therapy of diabetic macular edema. The aim was to study the association of single nucleotide polymorphic loci of VEGF and VEGFR2 genes, as well as functional and anatomical parameters with response to ranibizumab therapy in patients with diabetic macular edema. Material and methods. The study includes 145 patients (145 eyes) with diabetic macular edema. All the patients are divided into 2 groups: a positive response (A) and no response to angiogenic therapy (B). The positive response (group A) was the presence of a reduction of at least 10 % of the foveolar thickness (FT) from the baseline according to the OST data. In addition, the response category was assessed: a good response (A1): a reduction in FT by more than 25 %, and an increase in MCHO by more than 5 letters of ETDRS and a poor response (group A2): a reduction in FT of 10-25 % and an increase in MCRI by less than 5 letters ETDRS. Genomic DNA was selected from leukocytes in venous blood, genotyping was performed by real-time PCR using probes of hydrolysing samples. Results. 45 (33.6 %) patients demonstrated a good response (group A1) to therapy and 89 (66.4 %) had a «bad» response (group A2). In group A1, the decrease in FT occurred on average by 25.61 %, the increase in MHC was 0.21 ± 0.07, while in group A2, the visual acuity increased by 0.05, with the thickness of the retina reduction by 74.1 μm (19, 5 %). Rs3025039 of the VEGFA gene is associated with the change in PTC ( p = 0.02). The decrease in the volume of the macula is associated with the allele C rs2010963 of the VEGFA gene ( p = 0.03). For the carriers of the T allele, the locus rs3025039 of the VEGFA gene, on the contrary, shows a lower value of the decrease in the volume of the macula ( p = 0.03). The patients with the T / T genotype of the polymorphic locus rs3025039 of the VEGFA gene statistically respond to anti-VEGF therapy significantly worse. |
| first_indexed | 2024-03-08T14:34:21Z |
| format | Article |
| id | doaj.art-bbdd3cdb9122449da08ac2041d0457c5 |
| institution | Directory Open Access Journal |
| issn | 2410-2512 2410-2520 |
| language | Russian |
| last_indexed | 2025-03-14T13:20:11Z |
| publishDate | 2019-02-01 |
| publisher | Russian Academy of Sciences, Siberian Branch Publishing House |
| record_format | Article |
| series | Сибирский научный медицинский журнал |
| spelling | doaj.art-bbdd3cdb9122449da08ac2041d0457c52025-02-28T13:43:53ZrusRussian Academy of Sciences, Siberian Branch Publishing HouseСибирский научный медицинский журнал2410-25122410-25202019-02-01385111810.15372/SSMJ2018050260GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMAA. Z. Fursova0N. V. Chubar1M. S. Tarasov2M. A. Vasilyeva3S. A. Erkinova4A. S. Shadrina5E. A. Sokolova6M. L. Filipenko7Novosibirsk State Region Hospital; Novosibirsk State Medical University of Minzdrav of RussiaNovosibirsk State Region HospitalNovosibirsk State Region HospitalNovosibirsk State Region HospitalInstitute of Chemical Biology and Fundamental Medicine of SB RAS; Novosibirsk State UniversityNovosibirsk State Medical University of Minzdrav of Russia; Novosibirsk State UniversityInstitute of Chemical Biology and Fundamental Medicine of SB RAS; Novosibirsk State UniversityInstitute of Chemical Biology and Fundamental Medicine of SB RAS; Novosibirsk State UniversityApart from already established clinical factors, the polymorphic loci of the VEGF gene and its VEGFR2 receptor can have a significant effect on the response to anti-VEGF therapy of diabetic macular edema. The aim was to study the association of single nucleotide polymorphic loci of VEGF and VEGFR2 genes, as well as functional and anatomical parameters with response to ranibizumab therapy in patients with diabetic macular edema. Material and methods. The study includes 145 patients (145 eyes) with diabetic macular edema. All the patients are divided into 2 groups: a positive response (A) and no response to angiogenic therapy (B). The positive response (group A) was the presence of a reduction of at least 10 % of the foveolar thickness (FT) from the baseline according to the OST data. In addition, the response category was assessed: a good response (A1): a reduction in FT by more than 25 %, and an increase in MCHO by more than 5 letters of ETDRS and a poor response (group A2): a reduction in FT of 10-25 % and an increase in MCRI by less than 5 letters ETDRS. Genomic DNA was selected from leukocytes in venous blood, genotyping was performed by real-time PCR using probes of hydrolysing samples. Results. 45 (33.6 %) patients demonstrated a good response (group A1) to therapy and 89 (66.4 %) had a «bad» response (group A2). In group A1, the decrease in FT occurred on average by 25.61 %, the increase in MHC was 0.21 ± 0.07, while in group A2, the visual acuity increased by 0.05, with the thickness of the retina reduction by 74.1 μm (19, 5 %). Rs3025039 of the VEGFA gene is associated with the change in PTC ( p = 0.02). The decrease in the volume of the macula is associated with the allele C rs2010963 of the VEGFA gene ( p = 0.03). For the carriers of the T allele, the locus rs3025039 of the VEGFA gene, on the contrary, shows a lower value of the decrease in the volume of the macula ( p = 0.03). The patients with the T / T genotype of the polymorphic locus rs3025039 of the VEGFA gene statistically respond to anti-VEGF therapy significantly worse.https://sibmed.elpub.ru/jour/article/view/60diffuse macular edemaoptical coherence tomographyfoveolar thickness of retinaranibizumab |
| spellingShingle | A. Z. Fursova N. V. Chubar M. S. Tarasov M. A. Vasilyeva S. A. Erkinova A. S. Shadrina E. A. Sokolova M. L. Filipenko GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA Сибирский научный медицинский журнал diffuse macular edema optical coherence tomography foveolar thickness of retina ranibizumab |
| title | GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA |
| title_full | GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA |
| title_fullStr | GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA |
| title_full_unstemmed | GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA |
| title_short | GENETIC CRITERIA FOR ANTI-ANGIOGENIC THERAPY FOR TREATMENT OF DIABETIC MACULAR EDEMA |
| title_sort | genetic criteria for anti angiogenic therapy for treatment of diabetic macular edema |
| topic | diffuse macular edema optical coherence tomography foveolar thickness of retina ranibizumab |
| url | https://sibmed.elpub.ru/jour/article/view/60 |
| work_keys_str_mv | AT azfursova geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT nvchubar geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT mstarasov geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT mavasilyeva geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT saerkinova geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT asshadrina geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT easokolova geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema AT mlfilipenko geneticcriteriaforantiangiogenictherapyfortreatmentofdiabeticmacularedema |